Biohope presents the results of the BIOTRAIM study at the WTC’25 and they are selected among the most relevant abstracts in kidney transplantation
Biohope participated in the World Transplant Congress (WTC 2025) in San Francisco from 3 to 6 August 2025. We presented two oral communications on the results of the BIOTRAIM study.
The WTC 2025 was the most important event of the year in the field of transplantation, as this edition integrated the ATC (American Transplant Association) congress, which was held separately in previous years. With the aim of addressing the issues that concern nephrologists around the world the most, Dr Ali reviewed the 1,550 abstracts submitted to the congress in the field of renal transplantation, making an initial selection of 50 and a final selection of 30. The abstract presented by Biohope, with the results of the BIOTRAIM study, was selected and its results were presented at the closing plenary session (‘Reflection, Revelations and the Road Ahead’), in which the most relevant data from the congress are summarised.
The WTC congress represents a strategic opportunity for Biohope to raise awareness of its technology and the results of its clinical research studies among the international transplant community. It is a space for interaction with thought leaders and companies from around the world, as well as a forum for scientific updates in this field. Biohope aims to contribute innovatively to the advancement of personalisation and optimisation of immunosuppressive therapies in transplantation, and is preparing to enter the US market.
Click in the following links to access the Abstract 1 and Abstract 2 presented by Biohope at WTC25.
